Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 7/20 | 0.38 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12155976 | 0.98 | KDM4E (0.38) | KDM4EALDH1A1LMNAANO1STIM1 | |
| SCHEMBL12241330 | 0.92 | MEN1 (0.43) | KDM4EALDH1A1LMNAANO1NPSR1 | |
| SCHEMBL12155945 | 0.90 | MEN1 (0.43) | KDM4EALDH1A1LMNAANO1NPSR1 | |
| SCHEMBL12241341 | 0.86 | NPC1 (0.48) | KDM4EALDH1A1LMNAFABP4FABP5 | |
| SCHEMBL12155955 | 0.85 | IL2 (0.39) | KDM4EALDH1A1LMNAANO1STIM1 | |
| SCHEMBL16572616 | 0.85 | IL2 (0.40) | KDM4EALDH1A1LMNAANO1NPSR1 | |
| SCHEMBL12155975 | 0.84 | MEN1 (0.49) | KDM4EALDH1A1LMNAFABP4FABP5 | |
| SCHEMBL12155971 | 0.83 | IL2 (0.39) | KDM4EALDH1A1LMNAANO1STIM1 | |
| SCHEMBL12241334 | 0.82 | NPC1 (0.47) | KDM4EALDH1A1LMNAANO1FABP4 | |
| SCHEMBL12241333 | 0.81 | ALDH1A1 (0.42) | KDM4EALDH1A1LMNAFABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-2563776-B1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120751-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-8980629-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2015-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | KDM4E 4057/4885ALDH1A1 4409/4885LMNA 1306/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | KDM4E 4057/4885ALDH1A1 4409/4885LMNA 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.